Biocept Awarded Patent in China forIts Circulating Tumor Cell Platform

Share this news with your friends

Biocept has been awarded a Chinese Patent entitled, Devices and methods of cell capture and analysis. The issued patent covers methods and devices for the capture of rare cells of interest, including CTCs that are shed into the blood stream by solid tumors where an antibody, or mixture of antibodies, and a microchannel are used for cell capture, detection, and analysis. The patent encompasses the use of any biological sample type of interest and is the 33rd patent issued to Biocept that is core to its liquid biopsy technology and commercial testing platforms.